FDA Drug recall D-1257-2020
Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container, RX only, B Braun Medical Inc., Bethlehem, PA 180…
- FDA Drug
- Class I
- terminated
- Published 2020-05-06
On 2020-05-06 the FDA classified a Class I recall of Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container, RX only, B Braun Medical Inc., Bethlehem, PA 180… by B Braun Medical, citing failed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1257-2020 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2020-04-18 |
| Published | 2020-05-06 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | B Braun Medical |
| Distribution | US |
Product
Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container, RX only, B Braun Medical Inc., Bethlehem, PA 18018-3524, NDC 0264-3145-11
Reason
Failed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.
Identifiers
| code_info | Lot #: H8J812, Exp. Date 31 JUL 2020 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1257-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.